

# Analysis of Substrate-Binding Elements in OxIT, the Oxalate:Formate Antiporter of *Oxalobacter formigenes*<sup>†</sup>

Xicheng Wang, Rafiquel I. Sarker, and Peter C. Maloney\*

Department of Physiology, Johns Hopkins Medical School, Baltimore, Maryland 21205

Received April 18, 2006; Revised Manuscript Received July 6, 2006

**ABSTRACT:** An OxIT homology model suggests R272 and K355 in transmembrane helices 8 and 11, respectively, are critical to OxIT-mediated transport. We offer positive evidence supporting this idea by studying OxIT function after cysteine residues were separately introduced at these positions. Without further treatment, both mutant proteins had a null phenotype when they were reconstituted into proteoliposomes. By contrast, significant recovery of function occurred when proteoliposomes were treated with MTSEA (methanethiosulfonate ethylamine), a thiol-specific reagent that implants a positively charged amino group. In each case, there was a 2-fold increase in the Michaelis constant ( $K_M$ ) for oxalate self-exchange (from 80 to 160  $\mu$ M), along with a 5-fold (K355C) or 100-fold (R272C) reduction in  $V_{max}$  compared to that of the cysteine-less parental protein. Analysis by MALDI-TOF confirmed that MTSEA introduced the desired modification. We also examined substrate selectivity for the treated derivatives. While oxalate remained the preferred substrate, there was a shift in preference among other substrates so that the normal rank order (oxalate > malonate > formate) was altered to favor smaller substrates (oxalate > formate > malonate). This shift is consistent with the idea that the substrate-binding site is reduced in size via introduction of the  $SCH_2CH_2NH_3^+$  adduct, which generates a side chain that is  $\sim 1.85$  Å longer than that of lysine or arginine. These findings lead us to conclude that R272 and K355 are essential components of the OxIT substrate-binding site.

In the anaerobic bacterium *Oxalobacter formigenes*, the oxalate transporter, OxIT, allows the exchange of external divalent oxalate with the intracellular monovalent formate derived from oxalate decarboxylation (1, 2). The overall effect of these associated activities (exchange and decarboxylation) is generation of a proton-motive force to support membrane functions, including ATP synthesis, accumulation of growth substrates, and extrusion of waste products (1–4).

The way that OxIT helps establish a proton-motive force clarifies the role of similar cycles in other bacteria (4, 5) and broadens the variety of mechanisms known to generate metabolic energy. Equally interesting is the fact that OxIT also serves as a model for understanding structure–function relationships in the major facilitator superfamily (MFS),<sup>1</sup> a collection of evolutionarily related transporters encompassing 30–40% of the so-called “secondary” transport systems (6, 7). Thus, helix organization in the MFS was first described by electron crystallography of OxIT (8–10), confirming the presence of the 12 transmembrane  $\alpha$ -helices predicted by less direct methods (11, 12). More detailed organizational

features were revealed by later work, using X-ray crystallography of two other members of the MFS, LacY (13) and GlpT (14).

Analysis of OxIT hydropathy implicated K355 as a ligand-binding element, since this residue appeared to lie at the center of TM11 (11). Consistent with this idea, one finds that mutants lacking K355 are inactive (11, 15, 16) and that TM11 itself lines the transport pathway (15, 16). Since oxalate is a divalent anion at physiological pH (pH 7), it is of interest to ask if the OxIT hydrophobic sector has a second basic residue that facilitates substrate binding, and in this regard, valuable insight comes from an OxIT homology model (17) based on the X-ray structure of GlpT (14). This model supports the idea that K355 is used in ligand binding and points to R272, in TM8, as a likely partner in this event; early work (17) shows that R272, too, is required for normal OxIT function.

The work presented here provides additional evidence that supports the suggestion that K355 and R272 function in substrate binding and transport. In particular, we show these residues are essential for OxIT function, but not biogenesis or assembly, and we document that alterations of side chain architecture at these sites lead to changes in substrate specificity.

## EXPERIMENTAL PROCEDURES

**Mutagenesis and Protein Expression.** OxIT and its mutants were encoded within a 1.4 kb XbaI–HindIII fragment in pBluescript II SK<sup>+</sup> (11, 18). To suppress uninduced protein expression, Amp<sup>r</sup> plasmids harboring OxIT were carried in

<sup>†</sup> This work was supported by grants from the National Science Foundation (MCB-0235305) and the National Institutes of Health (GM24195).

\* To whom correspondence should be addressed: Department of Physiology, Johns Hopkins Medical School, Baltimore, MD 21205. Telephone: (410)955-8325. Fax: (410)955-4438. E-mail: pmaloney@jhmi.edu.

<sup>1</sup> Abbreviations: MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; MFS, major facilitator superfamily; MTS, methanethiosulfonate; MTSEA, methanethiosulfonate ethylamine; TM, transmembrane helix.

*Escherichia coli* strain XL1 along with plasmid pMS421 (Spec<sup>r</sup>, LacI<sup>q</sup>) (11). A fully functional cysteine-less variant of OxlT (C28G/C271A) with a C-terminal polyhistidine (His<sub>6</sub>) tail was used as parent to all single-cysteine mutations (15, 18). For protein expression, a colony from a fresh transformation was placed in LB broth with antibiotics and grown overnight at 37 °C. Cells were then diluted 100-fold into fresh medium and grown with shaking at 33–35 °C until A<sub>600</sub> reached 0.12, at which point OxlT expression was induced with 1 mM IPTG. Cells were harvested after an additional 3 h.

To detect OxlT in crude detergent extracts or after reconstitution into proteoliposomes, immunoblots were probed with antibody directed against polyhistidine; chemiluminescence was monitored using a Fuji LAS1000 gel documentation system (18).

**Reconstitution and Assays of OxlT Function.** Unless otherwise indicated, membranes prepared by osmotic lysis (1, 11) were solubilized in buffer containing 100 mM potassium oxalate, 50 mM potassium phosphate (pH 7), 20% (v/v) glycerol, 1.5% (w/v) octyl glucoside, and 0.5% (w/v) *E. coli* phospholipid (hydrated in distilled water). After clarification by centrifugation, solubilized protein (0.7–1 mg/mL) was reconstituted by detergent dilution (1, 19) to give proteoliposomes loaded with 100 mM potassium oxalate and 50 mM potassium phosphate (pH 7); after reconstitution, proteoliposomes were centrifuged, washed twice, and suspended as a stock using the same buffer in which potassium oxalate was replaced with potassium sulfate. In a few cases, as noted, the suspension and assay buffer contained 50 mM MOPS/K plus 100 mM potassium gluconate instead of 50 mM potassium phosphate plus 100 mM potassium sulfate, with equivalent results. During studies of protease sensitivity, 4-(2-aminoethyl)benzylsulfonyl fluoride, normally present at 0.25 mM, was omitted, and the solubilization buffer was altered so that the 100 mM potassium oxalate was replaced with either 50 mM potassium oxalate or 50 mM potassium sulfate (pH 7).

In routine experiments, [<sup>14</sup>C]oxalate transport was assessed in duplicate at room temperature in 1 mL volumes containing 0.1 mL of proteoliposome stock with 0.8 mL of suspension buffer and additives. The reaction was initiated by addition of 0.1 mL of 0.1 mM labeled oxalate, after which 0.2 mL samples were filtered using a Millipore GSTF filter (0.2 µm pore size) and washed twice with cold buffer. In some experiments, we evaluated apparent inhibition constants (*K*<sub>iapp</sub>) for competing substrates. In these tests, trace amounts of external unlabeled oxalate were removed by placing duplicate 0.2 mL aliquots of proteoliposomes onto the filter, followed by two washes using cold assay buffer. The vacuum was then disengaged, and samples were overlaid with 0.2 mL of a reaction mixture containing both [<sup>14</sup>C]oxalate and the competing compound (see ref 2). After a specified time (usually 30 s), the reaction was terminated by vacuum filtration, with washing as described above. MTS-linked agents were normally added in excess (1 mM) from 1 M stocks prepared in dimethyl sulfoxide; solvent-treated preparations served as controls.


**MALDI-TOF Mass Spectrometry.** Purified OxlT (0.3–1 mg/mL) was prepared by metal chelate affinity chromatography (15, 18), with elution at pH 4.3 using 100 mM potassium oxalate, 50 mM potassium acetate, 20% glycerol,

and 0.25% diheptanolyphosphatidylcholine (8, 9). Purified protein was desalted and recovered in 1% glycerol (at times also with 0.1% diheptanolyphosphatidylcholine) using gel filtration (CentriSep, Princeton Separations). For mass determination using MALDI-TOF mass spectrometry (20), sample wells were layered alternately with 2 µL volumes of the experimental solution and the sinapinic acid matrix [10 mg/mL 3,5-dimethoxy-4-hydroxycinnamic acid in 50% acetonitrile and 0.3% trifluoroacetic acid (w/v/v)]. For calibration, bovine serum albumin (1 mg/mL) was used either as an internal standard, by being mixed with the purified sample (1:10), or as an external control, by being placed in a well surrounded by samples; equivalent results were obtained with both methods. Spectra were acquired with a Voyager DE-STR MALDI-TOF mass spectrometer (Applied Biosystems).

## RESULTS

**R272 and K355 Facilitate OxlT Function.** In the OxlT homology model (17), R272 and K355 are positioned so that their side chains extend into the permeation pathway, where they are presumed to interact with the divalent substrate, oxalate. This hypothesis is consistent with the findings that among derivatives at these sites, only the R272K and K355R variants retain measurable function (11, 17), although at relatively low levels (see below). Such work did not identify whether these null responses relate to OxlT biogenesis or OxlT function, and to address this issue, we adopted a strategy resembling that used to identify a salt bridge in LacY (23, 24). Thus, we studied OxlT after reconstitution into proteoliposomes, where the already-assembled molecule is accessible to a variety of informative probes (see refs 15, 16, 21, and 22). Accordingly, we generated the single-cysteine R272C and K355C derivatives and studied their responses to MTSEA, which is expected to generate a new side chain, resembling lysine, by addition of the SCH<sub>2</sub>CH<sub>2</sub>-NH<sub>3</sub><sup>+</sup> adduct. While the cysteine-substituted variants show no detectable function under normal conditions, in both cases treatment of proteoliposomes with excess (1 mM) MTSEA led to restoration of OxlT function (Figure 1). This was especially striking for the K355C derivative, whose activity increased from effectively nil to nearly 20% of that of its parental protein (Figure 1A). On the same time scale, functional recovery for the MTSEA-treated R272C variant was considerably less. Even so, an extended assay showed evidence of functional recovery in this case as well (Figure 1B).


Further study revealed, for both variants, that half-maximal responses were elicited by relatively low (ca. 1 µM) levels of MTSEA (Figure 1C). Moreover, we also noted that similar functional recovery could be achieved by treatment before reconstitution. Thus, when normalized for protein recovered during reconstitution, activity found after MTSEA treatment of membranes (before solubilization) or detergent extract (before reconstitution) ranged from 84 to 117% (97 ± 8%, mean ± standard error) of that observed when proteoliposomes were treated (as in Figure 1). These data indicate that MTSEA modification may be studied in a variety of settings and that the reaction proceeds to the same extent when using membranes, detergent extracts, or proteoliposomes. Such data also suggest that MTSEA modification is not influenced by the presence of substrate, since 100 mM potassium oxalate was present in the detergent extracts, but not in the buffers



**FIGURE 1:** Functional rescue of OxIT by modification of K355C and R272C with MTSEA. (A and B) Oxalate-loaded proteoliposomes were prepared using membranes from cells expressing the cysteine-less parent and its K355C (A) or R272C (B) derivative. Ten minutes before the assay, proteoliposomes were given either 1 mM MTSEA (triangles) or an equivalent volume of the dimethyl sulfoxide solvent (circles). After addition of 0.1 mM [<sup>14</sup>C]oxalate, samples were taken for filtration and washing as indicated. In the insets, immunoblot analysis shows reconstitution of comparable levels of cysteine-less OxIT and the K355C (A) or R272C (B) derivative. (C) Proteoliposomes were exposed to solvent or MTSEA. Initial rates of [<sup>14</sup>C]oxalate transport are given as a percentage of that found with excess (2 mM) MTSEA. (D) Like panel A or B, using proteoliposomes with the K355C variant exposed to solvent (no addition) or the indicated agents at 1 mM: MTSEA; MTSPA, aminopropyl methanethiosulfonate; MTSMT, (trimethylammonium)methyl methanethiosulfonate; MTSCE, carboxyethyl methanethiosulfonate; MTSES, sulfonatoethyl methanethiosulfonate; MTSHE, hydroxyethyl methanethiosulfonate.

used to suspend membranes or proteoliposomes (see Experimental Procedures).

In other work, we modified K355C with alternative probes (Figure 1D). With one exception, we found no positive response for agents that introduce either a positive charge [(trimethylammonium)methyl methanethiosulfonate, (trimethylammonium)ethyl methanethiosulfonate (not shown), and 2-guanidinoethyl 2-guanidinoethanethiosulfonate (not shown)], a negative charge (carboxyethyl methanethiosulfonate and sulfonatoethyl methanethiosulfonate), or a neutral substituent (hydroxyethyl methanethiosulfonate). In the exceptional case, when aminopropyl methanethiosulfonate was used, the positive response was ~10% of that found with MTSEA. In these trials, we did not confirm that each probe introduced the expected modification. Instead, we presumed considerations of size and/or charge did not interfere with probe accessibility or reactivity because (i) we could document the expected modification after treatment with MTSEA itself (see below) and (ii) each probe can function as an inhibitor of variants with cysteine substitutions in pathway-lining residues in TM2, TM5, or TM11 (15, 16, 22; data not given).



**FIGURE 2:** MTSEA modification influences OxIT stability. Membranes containing the indicated OxIT variants were treated with either solvent (–) or MTSEA (+) as indicated, before preparation of detergent extracts (without protease inhibitor) with potassium oxalate omitted. After solubilization, equal portions of each extract were supplemented with 50 mM potassium sulfate (A and C) or 50 mM potassium oxalate (B and D) and kept at 4 or 25 °C for either 1 h (R272C) or 2 h (K355C) before samples were removed for SDS–PAGE and immunoblot analysis.

The low level of functional recovery for the R272C variant (Figure 1B) was of some concern. On one hand, since the modified target more closely resembles lysine as opposed to arginine, one might expect reduced activity, as for the R272K derivative (17). It was also feasible, however, that MTSEA modified only a small fraction of the target population. To address this issue, we relied on early work showing that in crude detergent extracts substrate binding protects OxIT from denaturation and proteolysis (18, 25; unpublished work). We reasoned that if MTSEA failed to modify the R272C variant, addition of substrate would fail to stabilize the population. In preliminary work, we confirmed that the cysteine-less parent exhibited the expected behavior (not shown). We then used immunoblot analysis to examine protease sensitivity of untreated samples or samples treated with MTSEA, in the absence and presence of oxalate. For example, when the K355C derivative was examined, incubation at room temperature led to proteolysis, and this did not appear markedly altered by MTSEA modification (Figure 2A). As expected, the MTSEA-treated sample was stabilized by oxalate, while proteolysis of the unmodified protein was unaffected by substrate (Figure 2B). A somewhat different pattern emerged when the R272 variant was studied. Thus, without MTSEA treatment, this mutant did not appear to be susceptible to proteolysis, yet after MTSEA modification, marked protease sensitivity was evident (Figure 2C). It is also clear that addition of substrate (oxalate) promotes stability of MTSEA-modified material, as it did for the K355C variant (Figure 2D). We draw two conclusions from these findings. First, it appears that part of the marked instability of OxIT may be attributed to the influence of R272, since in its absence (i.e., the R272C variant) OxIT has an extended lifetime in crude extracts (Figure 2C). Importantly, such stability was lost on modification by MTSEA, unless oxalate (Figure 2C) or formate (not shown) is present. Such observations focus directly on the entire population of probe-treated materials, without requiring assays of transport to report MTSEA modification. For this reason, we conclude that for the conditions of our experiments (Figures 1) use of MTSEA leads to modification of most, if not all, of the target population.

In more detailed work, we next characterized the kinetic behavior of both the R272C and K355C derivatives after



Table 1: Kinetic Parameters for R272 and K355 Mutants

sample <sup>a</sup>	$K_M$ ( $\mu$ M)	$V_{max}$ ( $\mu$ mol min <sup>-1</sup> mg <sup>-1</sup> )
cysteine-less OxIT	82 $\pm$ 7	1720 $\pm$ 210
R272K <sup>b</sup>	690 $\pm$ 72	50 $\pm$ 5
K355R <sup>b</sup>	5400	66
R272K/K355R	nd <sup>c</sup>	
R272C	nd <sup>c</sup>	
K355C	nd <sup>c</sup>	
R272C with MTSEA	165 $\pm$ 9	16 $\pm$ 1
K355C with MTSEA	160 $\pm$ 4	370 $\pm$ 110

<sup>a</sup> The C28G/C271A cysteine-less OxIT was parent to all variants except the K355R mutant, which was in wild-type background. Data are mean values  $\pm$  the standard error from four to seven separate trials. Where indicated, MTSEA was used at 1 mM (as in Figure 1A,B). <sup>b</sup> Summary data for the R272K mutant were noted earlier (17); analysis of the K355R mutant has been reported (16). <sup>c</sup> Not detectable in the extended assay (as in Figure 1B) (<0.01% parental specific activity).

Table 2: MALDI-TOF Mass Determinations of OxIT and Its Derivatives

sample <sup>a</sup>	expected mass (Da) <sup>b</sup>	observed mass (Da)		difference <sup>c</sup>
		no addition	with MTSEA	
wild type	45 620	45 635 $\pm$ 16	45 629 $\pm$ 14	-6
cysteine-less OxIT	45 542	45 537 $\pm$ 15	45 553 $\pm$ 20	16
R272C	45 489	45 494 $\pm$ 17	45 565 $\pm$ 14	71
K355C	45 517	45 541 $\pm$ 13	45 620 $\pm$ 3	79

<sup>a</sup> Mean values  $\pm$  the standard deviation for mass comparisons in three to six independent trials, except in a single case that reports the average ( $\pm$  range) of duplicate measurements. <sup>b</sup> Mass expected for OxIT lacking the N-terminal methionine, but with a C-terminal polyhistidine extension (see the text). <sup>c</sup> Difference between value with MTSEA and value with no addition.

modification by MTSEA. In both instances, it appeared that the major kinetic effect was an alteration of the maximal velocity for oxalate self-exchange, with a modest effect (2-fold increase) on the Michaelis constants for transport (Table 1). By contrast, the individual substitutions (R272K and K355R) gave substantial changes in both parameters (Table 1).

**MALDI-TOF Mass Spectrometry.** In the work summarized above, we presumed that cysteine modification restored the positive character of the target side chain by addition of the SCH<sub>2</sub>CH<sub>2</sub>NH<sub>3</sub><sup>+</sup> group, yielding a mass increment of 76 Da. Preliminary work suggested MALDI-TOF could monitor such changes in OxIT (45 kDa) without requiring analysis of peptide fragments, since in a series of eight comparisons involving multiple individual trials, the mean difference between observed and expected masses was 11  $\pm$  12 Da (mean  $\pm$  standard deviation) (see Table 2).

MALDI-TOF mass spectrometry of wild-type and cysteine-less OxIT (Figure 3) was instructive. In both instances, determined masses were lower (by 115 Da) than expected for the full OxIT sequence with its C-terminal His<sub>9</sub> extension. Given this result, and the reproducibility of the measurement (above), we concluded that affinity-purified material lacked the N-terminal methionine (131 Da), and all subsequent calculations were based on this assumption (Table 2). This post-translational change was not unexpected, since N-terminal microsequencing revealed the same modification after OxIT purification from its natural host, *O. formigenes*, using conventional techniques (2).




FIGURE 3: Mass determination of OxIT and its derivatives after exposure to MTSEA. At the bottom left, tracings show MALDI-TOF mass spectrometry for wild-type OxIT (WT) and its C28G/C271A derivative (GA), both treated with excess MTSEA (1 mM) prior to solubilization and purification. In the center, tracings show mass determinations for the K355C variant exposed to excess MTSEA (K355C<sub>MTSEA</sub>) and then treated with excess DTT (K355C). At the top right, mass determinations for the R272C derivative exposed to MTSEA (R272C<sub>MTSEA</sub>) and then to excess DTT (R272C) are shown.

Mass spectrometry of the R272C and K355C variants also proved to be informative (Figure 3). For this analysis, we exposed membranes to excess (1 mM) MTSEA so that the presence of oxalate during solubilization and purification could enhance protein stability (see Figure 2). We then incubated purified material with or without 200 mM DTT and used the mass difference between control and reduced samples as an index of the modification introduced by MTSEA. As anticipated (see ref 17), there was no significant modification by MTSEA of either the wild-type protein (mean difference of -6 Da) or cysteine-less OxIT (+16 Da) (Table 2), but for the R272C and K355C variants, exposure to MTSEA led to mass increases of 71 and 79 Da, respectively, values well beyond those expected of normal variation (11  $\pm$  12 Da) but comparable to the increments expected after MTSEA modification (76 Da). We conclude that MTSEA modification of R272C and K355C yields the desired product, with restoration of the electropositive character of the permeation pathway.

**Active Site Residues Determine Substrate Specificity.** The experiments described above suggest that R272 and K355 function in the binding of oxalate, the normal substrate of OxIT. We note that functional recovery after MTSEA modification was achieved by generating a new side chain (CH<sub>2</sub>SSCH<sub>2</sub>CH<sub>2</sub>NH<sub>3</sub><sup>+</sup>) whose full extension is longer than that of the normal partners, R272 or K355. If this novel side chain contributes to substrate binding, as implied by the results summarized earlier (Figure 1), one might expect MTSEA modification to be associated with altered substrate specificity due to changes in binding site architecture. To test this idea, we screened a number of potential substrates as competitors of [<sup>14</sup>C]oxalate transport by parental and derivative proteins (Table 3). In such work, proteoliposomes were treated with 1 mM MTSEA, and initial rates of the oxalate self-exchange (0.1 mM substrate) were measured in the absence and presence of potential competitors present at a 100-fold excess (10 mM). As expected, oxalate itself

Table 3: Substrate Specificity of OxIT and Its Derivatives

sample <sup>a</sup>	residual [ <sup>14</sup> C]oxalate transport (%)			
	parent	R272K	R272C with MTSEA	K355C with MTSEA
no addition	100	100	100	100
with oxalate	1 ± 0.1	9 ± 0.8	5 ± 1.4	3 ± 0.5
with malonate	34 ± 3.1	39 ± 5.9	80 ± 3.1	70 ± 8
with nitrate <sup>b</sup>	51 ± 10	36 ± 4.5	28 ± 4	11 ± 3
with formate	59 ± 4.4	55 ± 3.6	40 ± 1.6	7 ± 0.4
with glyoxylate	69 ± 6.1	69 ± 1.7	52 ± 1.3	64 ± 1.0
with bicarbonate <sup>b</sup>	80 ± 8.8	95 ± 6.6	72 ± 3.7	84 ± 4.2
with acetate	81 ± 6.5	72 ± 1.2	93 ± 2.0	45 ± 1.7
with lactate	82 ± 2.8	103 ± 2.7	119 ± 3.7	86 ± 4.3
with glycolate	88 ± 8.9	86 ± 1.9	95 ± 3.4	62 ± 3.4

<sup>a</sup> Mean values ± the standard deviation from three separate experiments reporting relative accumulation of labeled oxalate by proteoliposomes for initial rate determinations, using 0.1 mM [<sup>14</sup>C]oxalate with potassium sulfate (no addition) or the potassium salt of the indicated competing substrates present at 10 mM. <sup>b</sup> Using assay buffer in which 50 mM MOPS/K and 100 mM potassium gluconate replaced 50 mM potassium phosphate and 100 mM potassium sulfate. Control experiments showed this substitution had no significant effect on OxIT function.

(<sup>−</sup>OOCCOO<sup>−</sup>) exhibited the highest degree of inhibition, since among known OxIT substrates oxalate has the highest apparent affinity (11, 27). Malonate (<sup>−</sup>OOCCH<sub>2</sub>COO<sup>−</sup>) and formate (HCOO<sup>−</sup>) also gave marked inhibition, consistent with earlier studies that identified them as OxIT substrates (11, 27). Less effective inhibitors included glyoxylate (HCOCOO<sup>−</sup>), acetate (H<sub>3</sub>CCOO<sup>−</sup>), lactate (CH<sub>3</sub>HCOHCOO<sup>−</sup>), bicarbonate (HCO<sub>3</sub><sup>−</sup>), and glycolate (H<sub>2</sub>COHCOO<sup>−</sup>), none of which appeared to be effective substrates in this test. A similar rank order was observed for the R272K variant [the low activity of the K355R mutant (Table 1) precluded its use in this work], but significant differences emerged in tests with the MTSEA-treated cysteine substitution variants. For example, in both the R272C and K355C proteins, there was a blunted response to malonate, suggesting these variants have a significantly reduced affinity for this substrate. By contrast, the response to formate was strengthened, especially for the K355C protein, suggesting an enhanced affinity for this anion.

A recent study of the MFS nitrate transporter, NtrA, suggested that paired arginine residues, one each in TM2 and TM8, might serve as substrate (anion) binding sites (26) as in GlpT and UhpT (14, 25), and this raised the possibility that OxIT and its variants might accept inorganic as well as organic anions. In added tests, therefore, we examined a panel of inorganic anions as possible OxIT substrates, including bicarbonate, chloride, dithionite, fluoride, nitrate, nitrite, perchlorate, perchlorite, phosphate, sulfate, sulfite, and thiocyanate. Among these, only nitrate and nitrite gave significant inhibition of the oxalate self-exchange (Table 3 and data not shown), suggesting a limited capacity of OxIT to accept inorganic anions.

The crude screen used to identify potential substrate specificity alterations (Table 3) prompted more explicit tests of MTSEA-modified variants with regard to their responses to malonate, formate, and nitrate (Figure 4). In each case, we confirmed the discrepancies noted in the preliminary screen. Thus, for malonate, we obtained *K*<sub>iapp</sub> values (mean ± standard error) of 6.1 ± 0.4 mM for the parental protein, comparable to that found earlier (25), but significantly




FIGURE 4: Altered substrate specificity for OxIT variants exposed to MTSEA. To determine apparent inhibition constants, the initial rates of 0.1 mM [<sup>14</sup>C]oxalate transport were determined in the presence of malonate (A), formate (B), or nitrate (C). Proteoliposomes treated with 1 mM MTSEA contained either cysteine-less OxIT (○) or its K355C (□) or R272C (●) derivative. Observed rates were normalized by expressing them as a fraction (*F*) of the rate found in the absence of inhibitor, and apparent *K*<sub>i</sub> values (*K*<sub>iapp</sub>) were determined as the inhibitor concentrations yielding 50% inhibition of [<sup>14</sup>C]oxalate transport. *K*<sub>iapp</sub> values cited in the text summarize three independent experiments as shown here. Assuming simple competitive inhibition and the kinetic parameters in Table 1, the observed *K*<sub>iapp</sub> values for malonate would reflect true *K*<sub>i</sub> values of 72, 53, and 2.7 mM for R272C<sub>MTSEA</sub>, K355C<sub>MTSEA</sub>, and cysteine-less OxIT, respectively. For formate, the respective *K*<sub>i</sub> values would be 0.31 mM (K355C<sub>MTSEA</sub>) and 0.71 mM (cysteine-less OxIT); for nitrate, these *K*<sub>i</sub> values would be 0.7 mM (K355C<sub>MTSEA</sub>) and 1.8 mM (cysteine-less OxIT).

elevated values of  $115 \pm 3.6$  and  $51 \pm 13$  mM for the modified R272C and K355C proteins, respectively (Figure 4A). By contrast, enhanced inhibition of K355C by formate and nitrate (Table 3) correlated with 3–4-fold lowered  $K_{iapp}$  values for this derivative relative to that of its unmodified parent (Figure 4B,C). (The modified R272C variant was not examined.) For formate,  $K_{iapp}$  for these conditions was lowered from  $1.6 \pm 0.3$  to  $0.5 \pm 0.1$  mM; for nitrate,  $K_{iapp}$  fell from  $4.1 \pm 0.8$  to  $1.1 \pm 0.3$  mM. Such modifications of substrate specificity provide further evidence that R272 and K355 play direct roles in substrate binding.

## DISCUSSION

Examination of the OxlT homology model (17), as well as earlier biochemical work (11, 15, 16), suggests that two positively charged residues (R272 and K355) serve as ligand-binding elements for the anionic OxlT substrates. The work reported here supports this hypothesis, in part by showing that a requirement for positive charge at these positions reflects requirements for OxlT function, rather than biogenesis. More importantly, we document that side chain modifications at these sites can have an impact on substrate specificity.

Early work showed that substitution at position 272 or 355 abolished OxlT function unless the basic character of the original residue was preserved (15–17), but even like substitutions (e.g., R272K or K355R) yield substantially diminished catalytic activity (Table 1), suggesting that side chain architecture in this region is critical. Those findings did not clarify whether such effects reflect roles crucial to substrate transport alone or whether long-range effects in protein folding and/or assembly might also be relevant to the observed phenotype. To address such issues, we analyzed the R272C and K355C null mutants after reconstitution, using MTSEA to restore the positive character of these positions. That function was restored in both instances (Figure 1) argues against the idea that the normal side chains contribute importantly to protein assembly and instead points to their participation in OxlT function. This conclusion is reinforced by findings related to OxlT stability, which show that MTSEA modification restores the capacity for substrate (oxalate) stabilization (Figure 2), a phenomenon that requires ligand binding (18, 25).

Several well-characterized anion transporters in the MFS, such as GltT, UhpT, NtrA, and OxlT, share a common feature in that substrate binding appears to require interactions with two positively charged residues on the permeation pathway (14, 16, 23, 26). Thus, no function is recorded when either of the paired arginines in UhpT and GltT is replaced with lysine (14, 23; unpublished work), and in the same fashion, NtrA displays only low residual activity when either of its paired arginine residues is substituted with lysine (26). In OxlT, it is also clear that arginine and lysine are poor substitutes for one another (Table 1), and this likely explains the low functional recovery after MTSEA treatment of R272C, despite the fact that this target appears to be fully modified (Figure 2). This line of reasoning also applies in the case of K355C, which shows little or no functional recovery when non-lysine-like side chains are generated by exposure to MTS-linked probes, even those that introduce positive charge (Figure 1D).

These considerations prompted us to ask whether OxlT substrate specificity was altered upon restoration of function by MTSEA in the R272C and K355C mutants. If so, we suggest this would be strong direct evidence that these positions are involved in substrate recognition. Indeed, we find that altering side chain architecture modulates selectivity among three potential substrates [malonate, formate, and nitrate (Table 3 and Figure 4)] and offer simple speculation that may partly account for such results. Thus, while side chain length is approximately the same for lysine and arginine, the side chain generated by MTSEA modification ( $\text{CH}_2\text{SSCH}_2\text{CH}_2\text{NH}_3^+$ ) would extend an additional 1.85 Å into the binding domain. Comparisons of the GltT X-ray structure (14) and the OxlT homology model (17) suggest this domain is normally a thin  $\sim 3 \text{ Å} \times \sim 10 \text{ Å}$  discoid, so intrusion of the larger side chain would reduce the (putative) active site cross-sectional area and volume. It follows that this might introduce bias against larger substrates, as observed for the comparison of malonate and oxalate (Figure 4). One might also expect that binding of smaller substrates could be enhanced. A highly developed argument shows how geometric aspects of a permeation pathway contribute to selectivity in ion channels (28), and while application of such considerations to OxlT remains speculative, the observed changes in substrate specificity do give strong support to the hypothesis that R272 and K355 contribute to ligand binding in OxlT.

## ACKNOWLEDGMENT

We thank The Johns Hopkins A. B. Mass Spectrometry/Proteomic Facility for providing training in MALDI-TOF and for access to the necessary equipment.

## REFERENCES

1. Anantharam, V., Allison, M. J., and Maloney, P. C. (1989) Oxalate: formate exchange. The basis for energy coupling in *Oxalobacter*, *J. Biol. Chem.* 264, 7244–7250.
2. Ruan, Z. S., Anantharam, V., Crawford, I. T., Ambudkar, S. V., Rhee, S. Y., Allison, M. J., and Maloney, P. C. (1992) Measurement of the substrate dissociation constant of a solubilized membrane carrier. Substrate stabilization of OxlT, the anion exchange protein of *Oxalobacter formigenes*, *J. Biol. Chem.* 267, 10537–10543.
3. Abe, K., Hayashi, H., and Maloney, P. C. (1996) Exchange of aspartate and alanine. Mechanism for development of a proton-motive force in bacteria, *J. Biol. Chem.* 271, 3079–3084.
4. Lolkema, J. S., Poolman, B., and Konings, W. N. (1998) Bacterial solute uptake and efflux systems *Curr. Opin. Microbiol.* 1, 248–253.
5. Abe, K., Ohnishi, F., Yagi, K., Nakajima, T., Higuchi, T., Sano, M., Machida, M., Sarker, R. I., and Maloney, P. C. (2002) Plasmid-encoded *asp* operon confers a proton motive metabolic cycle catalyzed by an aspartate-alanine exchange reaction, *J. Bacteriol.* 11, 2906–2913.
6. Pao, S. S., Paulsen, I. T., and Maier, M. H., Jr. (1998) Major facilitator superfamily, *Microbiol. Mol. Biol. Rev.* 62, 1–34.
7. Saier, M. H., Jr., and Busch, W. (2002) The transporter classification (TC) system, (2002) *Crit. Rev. Biochem. Mol. Biol.* 37, 287–337.
8. Heymann, J. A., Sarker, R., Hirai, T., Shi, D., Milne, J. L., Maloney, P. C., and Subramaniam, S. (2001) Projection structure and molecular architecture of OxlT, a bacterial membrane transporter, *EMBO J.* 20, 4408–4413.
9. Hirai, T., Heymann, J., Shi, D., Sarker, R. I., Maloney, P. C., and Subramaniam, S. (2002) Three-dimensional structure of a bacterial oxalate transporter, *Nat. Struct. Biol.* 9, 597–600.



10. Hirai, T., Heymann, J. A., Maloney, P. C., and Subramaniam, S. (2003) Structural model for 12-helix transporters belonging to the major facilitator superfamily, *J. Bacteriol.* 185, 1712–1718.
11. Abe, K., Ruan, Z.-S., and Maloney, P. C. (1996) Cloning, sequencing, and expression in *Escherichia coli* of OxlT, the oxalate:formate exchange protein of *Oxalobacter formigenes*, *J. Biol. Chem.* 271, 6789–6793.
12. Foster, D. L., Boublik, M., and Kaback, H. R. (1983) Structure of the *lac* carrier protein of *Escherichia coli*, *J. Biol. Chem.* 258, 31–34.
13. Abramson, J., Smirnova, I., Kasho, V., Verner, G., Kaback, H. R., and Iwata, S. (2003) Structure and mechanism of the lactose permease of *Escherichia coli*, *Science* 301, 610–615.
14. Huang, Y., Lemieux, M. J., Song, J., Auer, M., and Wang, D. N. (2003) Structure and mechanism of the glycerol 3-phosphate transporter of *Escherichia coli*, *Science* 301, 616–620.
15. Fu, D., and Maloney, P. C. (1998) Structure–function relationships in OxlT, the oxalate/formate transporter of *Oxalobacter formigenes*. Topological features of transmembrane helix 11 as visualized by site-directed fluorescent labeling, *J. Biol. Chem.* 273, 17962–17967.
16. Fu, D., Sarker, R. I., Abe, K., Bolton, E., and Maloney, P. C. (2001) Structure/function relationships in OxlT, the oxalate-formate transporter of *Oxalobacter formigenes*. Assignment of transmembrane helix 11 to the translocation pathway, *J. Biol. Chem.* 276, 8753–8760.
17. Yang, Q., Wang, X., Ye, L., Mentrikoski, M., Mohammadi, E., Kim, Y. M., and Maloney, P. C. (2005) Experimental tests of a homology model for OxlT, the oxalate transporter of *Oxalobacter formigenes*, *Proc. Natl. Acad. Sci. U.S.A.* 102, 8513–8518.
18. Fu, D., and Maloney, P. C. (1997) Evaluation of secondary structure of OxlT, the oxalate transporter of *Oxalobacter formigenes*, by circular dichroism spectroscopy, *J. Biol. Chem.* 272, 2129–2135.
19. Ambudkar, S. V., and Maloney, P. C. (1986) Bacterial anion exchange. Use of osmolytes during solubilization and reconstitution of phosphate-linked antiporter from *Streptococcus lactis*, *J. Biol. Chem.* 261, 10079–10086.
20. Cadene, M., and Chait, B. T. (2000) A robust, detergent-friendly method for mass spectrometric analysis of integral membrane proteins, *Anal. Chem.* 72, 5655–5658.
21. Ye, L., Jia, Z., Jung, T., and Maloney, P. C. (2001) Topology of OxlT, the oxalate transporter of *Oxalobacter formigenes*, determined by site-directed fluorescence labeling, *J. Bacteriol.* 183, 2490–2496.
22. Ye, L., and Maloney, P. C. (2002) Structure/function relationships in OxlT, the oxalate/formate antiporter of *Oxalobacter formigenes*: Assignment of transmembrane helix 2 to the translocation pathway, *J. Biol. Chem.* 277, 20372–20378.
23. Dunten, R. L., Sahin-Toth, M., and Kaback, H. R. (1993) Role of the charge pair aspartic acid-237-lysine-358 in the lactose permease of *Escherichia coli*, *Biochemistry* 32, 3139–3145.
24. Sahin-Toth, M., and Kaback, H. R. (1993) Role of the charge pair aspartic acid-237-lysine-358 in the lactose permease of *Escherichia coli*, *Biochemistry* 32, 10027–10035.
25. Fann, M.-C., Davies, A. H., Varadhachary, A., Kuroda, T., Sevier, C., Tsuchiya, T., and Maloney, P. C. (1998) Identification of two essential arginine residues in UhpT, the sugar phosphate antiporter of *Escherichia coli*, *J. Membr. Biol.* 164, 187–195.
26. Unkles, S. E., Rouch, D. A., Wang, Y., Siddiqi, M. Y., Glass, A. D., and Kinghorn, J. R. (2004) Two perfectly conserved arginine residues are required for substrate binding in a high-affinity nitrate transporter, *Proc. Natl. Acad. Sci. U.S.A.* 101, 17549–17554.
27. Maloney, P. C., Anantharam, V., and Allison, M. J. (1992) Measurement of the substrate dissociation constant of a solubilized membrane carrier. Substrate stabilization of OxlT, the anion exchange protein of *Oxalobacter formigenes*, *J. Biol. Chem.* 267, 10531–10536.
28. Hille, B. (1992) *Ionic Channels of Excitable Membranes*, 2nd ed., pp 347–376, Sinauer Associates, Inc., Sunderland, MA.

BI060746V